• 1. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 4. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

3-(3-N,N-Dimethylsulfamoylphenyl)benzoic Acid: A Comprehensive Overview

3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid (CAS No. 1261941-80-3) is a versatile compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications, particularly in the development of new drugs targeting specific biological pathways.

The molecular structure of 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid consists of a benzoic acid moiety linked to a substituted phenyl ring through a sulfonamide group. The presence of the N,N-dimethylsulfamoyl group imparts specific chemical and biological properties that make this compound an attractive candidate for drug design and development.

Recent studies have highlighted the multifaceted biological activities of 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid. One notable area of research is its potential as an anti-inflammatory agent. In vitro and in vivo studies have demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, which are key mediators of inflammatory responses. This property makes it a promising candidate for the treatment of chronic inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

Moreover, 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid has shown potential in cancer research. Preclinical studies have indicated that this compound can induce apoptosis in various cancer cell lines, including those derived from breast, lung, and colon cancers. The mechanism of action appears to involve the modulation of signaling pathways that regulate cell survival and proliferation, such as the PI3K/Akt and MAPK pathways. These findings suggest that 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid could be developed into a novel anticancer agent with broad-spectrum activity.

In addition to its anti-inflammatory and anticancer properties, 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid has also been investigated for its potential as a neuroprotective agent. Studies have shown that this compound can protect neuronal cells from oxidative stress and neurotoxicity induced by various insults, such as glutamate excitotoxicity and β-amyloid toxicity. These neuroprotective effects are attributed to its ability to scavenge free radicals and modulate intracellular signaling pathways involved in neuronal survival.

The pharmacokinetic properties of 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid have also been studied extensively. Research has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles, making it suitable for further development as a therapeutic agent. Its oral bioavailability is relatively high, and it demonstrates good tissue penetration, which is crucial for its effectiveness in treating systemic diseases.

Safety and toxicity assessments are essential components of drug development. Preclinical studies have indicated that 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid is generally well-tolerated at therapeutic doses. However, like any new chemical entity, it is important to conduct comprehensive safety evaluations to ensure its long-term use is safe and effective.

In conclusion, 3-(3-N,N-Dimethylsulfamoylphenyl)benzoic acid (CAS No. 1261941-80-3) represents a promising compound with diverse biological activities and therapeutic potential. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in the fields of medicinal chemistry and pharmaceutical sciences. Ongoing studies are expected to uncover additional applications and optimize its use in clinical settings.

• 7326-73-0(3-Dimethylsulfamoylbenzoic acid)
• 582325-19-7([1,1'-Biphenyl]-4-carboxylic acid, 3'-[(dimethylamino)sulfonyl]-)
• 1261983-62-3([1,1'-Biphenyl]-3-carboxylic acid, 4'-[(dimethylamino)sulfonyl]-)
• 1206-37-7(4-(dimethylsulfamoyl)benzoic acid)
• 89001-58-1(5-(Dimethylamino)Sulfonyl-2-Methylbenzoic Acid)
• 1261913-98-7(3-[4-(Dimethylsulfamoyl)phenyl]-2-methylbenzoic acid)
• 1261893-89-3(95%)
• 851168-78-0(3-(dimethylsulfamoyl)-4,5-dimethylbenzoic acid)
• 582325-14-2([1,1'-BIPHENYL]-4-CARBOXYLIC ACID, 3'-[(METHYLAMINO)SULFONYL]-)
• 1261981-44-5(3-Chloro-5-[3-(dimethylsulfamoyl)phenyl]benzoic acid)